CNMD - CONMED Corporation
| Previous Close | 68.03 |
| Open | 68.02 |
| Bid | 67.49 x 100 |
| Ask | 67.62 x 1400 |
| Day's Range | 67.52 - 68.70 |
| 52 Week Range | 49.22 - 83.49 |
| Volume | 106,713 |
| Avg. Volume | 193,252 |
| Market Cap | 1.902B |
| Beta (3Y Monthly) | 0.92 |
| PE Ratio (TTM) | 27.03 |
| EPS (TTM) | 2.50 |
| Earnings Date | Jan 29, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | 0.80 (1.16%) |
| Ex-Dividend Date | 2018-12-13 |
| 1y Target Est | 78.75 |
Markit•yesterdaySee what the IHS Markit Score report has to say about Conmed Corp.
Conmed Corp NASDAQ/NGS:CNMD
- GlobeNewswire•2 days ago
Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International — Fundamental Analysis, Key Performance Indications
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•6 days ago
CONMED Corporation Announces Quarterly Cash Dividend
CONMED Corporation (CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on January 7, 2019 to all shareholders of record as of December 14, 2018. CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of CNMD earnings conference call or presentation 1-Nov-18 8:30pm GMT
Q3 2018 Conmed Corp Earnings Call
- Simply Wall St.•8 days ago
Is CONMED Corporation (NASDAQ:CNMD) An Attractive Dividend Stock?
Dividends can be underrated but they form a large part of investment returns, playing an important role in compounding returns in the long run. Historically, CONMED Corporation (NASDAQ:CNMD) has paid Read More...
- Business Wire•9 days ago
CONMED Corporation to Present at the Jefferies London Healthcare Conference
CONMED Corporation (CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Jefferies London Healthcare Conference at 8:40 a.m. GMT (3:40 a.m. ET) on Wednesday, November 14, 2018 in London, UK. CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology.
- Zacks•9 days ago
CONMED (CNMD) Beats Earnings, Revenue Estimates in Q3
Solid domestic and international sales drive CONMED's (CNMD) results in Q3. Also, raised sales guidance encourages.
- Zacks•13 days ago
Conmed (CNMD) Q3 Earnings and Revenues Top Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 2.22% and 1.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•13 days ago
Conmed: 3Q Earnings Snapshot
The Utica, New York-based company said it had net income of 20 cents per share. Earnings, adjusted for one-time gains and costs, were 46 cents per share. The results exceeded Wall Street expectations. ...
- Business Wire•13 days ago
CONMED Corporation Announces Third Quarter 2018 Financial Results
CONMED Corporation today announced financial results for the third quarter ended September 30, 2018.
Markit•25 days agoSee what the IHS Markit Score report has to say about Conmed Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Business Wire•27 days ago
CONMED Corporation to Announce Third Quarter 2018 Financial Results on November 1, 2018
CONMED Corporation (CNMD) today announced that it will report financial results for the third quarter of fiscal year 2018 after the market close on Thursday, November 1, 2018. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 844-889-7792 (domestic) or 661-378-9936 (international) and refer to the passcode 3386328.
- GlobeNewswire•last month
Recent Analysis Shows Carriage Services, Century Communities, Enable Midstream Partners, LP, MCBC, CONMED, and Chatham Lodging Trust (REIT) Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Oct. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•last month
Here's Why You Should Hold CONMED Stock in Your Portfolio
Despite aggressive rivalry in the MedTech space, CONMED (CNMD) to gain from its unique offerings and an extensive product portfolio.
Markit•last monthSee what the IHS Markit Score report has to say about Conmed Corp.
Conmed Corp NASDAQ/NGS:CNMD
- Simply Wall St.•2 months ago
Is CONMED Corporation (NASDAQ:CNMD) Attractive At Its Current PE Ratio?
This analysis is intended to introduce important early concepts to people who are starting to invest and want to start learning about core concepts of fundamental analysis on practical examplesRead More...
- Business Wire•3 months ago
CONMED Corporation to Present at the Morgan Stanley Global Healthcare Conference
CONMED Corporation (CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, September 12, 2018 in New York, NY. CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology.
Markit•3 months agoSee what the IHS Markit Score report has to say about Conmed Corp.
Conmed Corp NASDAQ/NGS:CNMD
- Business Wire•3 months ago
CONMED Corporation Announces Quarterly Cash Dividend
CONMED Corporation (CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 8, 2018 to all shareholders of record as of September 14, 2018. CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
- Investopedia•3 months ago
Medical Device Stocks on the Move
On a relative basis, the sector continues to digest its strong year-to-date gains and work off a bearish momentum divergence by consolidating above our previous price objective at 0.734. An individual name in the sector breaking out is Masimo Corporation ( MASI). It has been consolidating for the past 18 months, and this push to new all-time highs signals the resumption of its long-term uptrend.
- Zacks•3 months ago
CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance
CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.
Markit•3 months agoSee what the IHS Markit Score report has to say about Conmed Corp.
Conmed Corp NASDAQ/NGS:CNMD
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of CNMD earnings conference call or presentation 1-Aug-18 8:30pm GMT
Q2 2018 Conmed Corp Earnings Call
- Zacks•3 months ago
Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 2.22% and 2.88%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
